MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.550
-0.040 (-2.52%)
At close: Mar 6, 2026, 4:00 PM EST
1.551
+0.001 (0.06%)
After-hours: Mar 6, 2026, 7:01 PM EST
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees
9
Change (1Y)
1
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,801,778
Market Cap
4.97M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| Calidi Biotherapeutics | 28 |
| VivoSim Labs | 14 |
| Genprex | 13 |
| Purple Biotech | 9 |
| Revelation Biosciences | 9 |
| Xenetic Biosciences | 2 |
| Cyclerion Therapeutics | 1 |
MTVA News
- 3 days ago - MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - PRNewsWire
- 18 days ago - MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference - PRNewsWire
- 21 days ago - MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug - Benzinga
- 22 days ago - MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 - PRNewsWire
- 4 weeks ago - MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel - PRNewsWire
- 7 weeks ago - MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option - PRNewsWire
- 7 weeks ago - MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering - PRNewsWire
- 2 months ago - MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile - PRNewsWire